Which ISO 10993-7 Edition Governs an EO Residual CoA in 2026: Why ISO 10993-7:2026 Is Not FDA Recognition 2-275, Why the 25 May 2026 Part 1 Update Did Not Move Part 7, and Why MDCG 2024-13 Still Names EN ISO 10993-7:2008+A1:2022

Does ISO 10993-7:2026 publication mean FDA, the EU or China have moved the residual file?

When international distributors, private-label brand owners, or hospital procurement teams qualify an ethylene-oxide-sterilized single-use device—such as a disposable circumcision device, an anastomat kit, or a surgical stapler—they routinely receive a Certificate of Analysis (CoA) or laboratory report citing ISO 10993-7.¹ In mid-2026, a growing number of laboratory test headers, contract-sterilizer memos, and testing agency sales brochures have begun displaying ISO 10993-7:2026, asserting that the third edition is now the mandatory global standard governing allowable ethylene oxide (EO) and ethylene chlorohydrin (ECH) residues.¹

That assertion flattens a critical regulatory boundary: publication by the International Organization for Standardization (ISO) is not regulatory recognition by sovereign authorities.⁴⁹ In April 2026, ISO technical committee ISO/TC 194 published the third edition, ISO 10993-7:2026 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals), comprising 122 pages.¹ In ISO's official standard catalogue, this third edition officially cancels and replaces the second edition (ISO 10993-7:2008), along with Technical Corrigendum 1:2009 and Amendment 1:2019.¹²

However, medical device market clearance, import clearance, and lot release are governed by the statutory recognitions of national competent authorities, not the publication calendar of ISO committees.¹⁰ An examination of the global regulatory landscape in September 2026 demonstrates that neither the United States Food and Drug Administration (FDA), nor the European Union under Regulation (EU) 2017/745 (MDR), nor the Chinese National Medical Products Administration (NMPA) has converted ISO 10993-7:2026 into an exclusive, in-force mandatory release standard.⁴⁷¹²

Search-engine overviews and trade summaries frequently confuse this point. For example, algorithmic summaries generated on 9 September 2026 for queries surrounding ISO 10993-7:2026 report that the third edition governs allowable limits, while summaries for FDA consensus standards claim that FDA simply recognizes 'ISO 10993-7' without specifying the edition or recognition number. As demonstrated in Table 1, conflating ISO publication with regulatory recognition exposes buying organizations to serious audit and release vulnerabilities across all three major trading zones.⁴⁵⁷

What does FDA Rec 2-275 still name, and why did the 25 May 2026 Part 1 update not move Part 7?

The authoritative source for medical device standards recognition in the United States is the FDA CDRH Recognized Consensus Standards database.⁴ A live interrogation of this database on 9 September 2026 for designation number 10993-7 yields exactly 1 result: Recognition Number 2-275.⁵

According to the official FDA Supplementary Information Sheet, Recognition 2-275 was published in Federal Register Recognition List Number 054 with an entry date of 6 July 2020.⁴ The standard title is recorded as: ISO 10993-7 Second edition 2008-10-15 Biological evaluation of medical devices - Part 7: Ethylene oxide sterilization residuals [Including: Technical Corrigendum 1 (2009), AMENDMENT 1: Applicability of allowable limits for neonates and infants (2019)].⁴ The extent of recognition is 'Complete standard', and the database record confirms that the entry was last updated on 25 May 2026.⁴

The significance of the 25 May 2026 date cannot be overstated. On that exact date, the FDA published Federal Register Recognition List Number 066.⁶ In that update, FDA added Recognition Number 2-313, a partial recognition of ISO 10993-1 Sixth edition 2025-11 (Biological evaluation of medical devices - Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process).⁶ The agency also established a transition window: FDA will continue to accept Declarations of Conformity to the fifth edition (Recognition 2-258, ISO 10993-1:2018) in premarket submissions until 1 July 2029.⁶ Rec 2-313 is not a full Part 1 passport: FDA does not recognise the phrase “consumer products” in clause 6.5.11.3 or clause 6.9 (biological risk estimation).⁶

Many industry commentaries and consulting blogs made a hasty generalization, assuming that because FDA updated its biocompatibility recognition list on 25 May 2026 to incorporate the 2025 edition of Part 1, the entire ISO 10993 family—including the newly published ISO 10993-7:2026—had transitioned.⁴⁶ That assumption is false on the public database. While FDA added Rec 2-313 for Part 1, a search for designation 10993-7 still returns only Rec 2-275.⁴⁵ FDA did not assign a new recognition number to ISO 10993-7:2026, did not publish a partial recognition of the third edition, and did not establish a Part 7 transition calendar analogous to the 1 July 2029 date printed for Part 1.⁴⁶

As detailed in our review of US biocompatibility strategy in the ISO 10993 biocompatibility file review guide, Part 1 establishes the overarching biological evaluation plan (BEP), while Part 7 governs the specific physical release thresholds for gaseous sterilants.⁶ Furthermore, as noted in our QMSR production and process controls review, a manufacturer submitting a premarket notification (510(k)) or defending a batch release during an FDA quality system inspection must cite the specific consensus standard recognized under Section 514(c) of the Federal Food, Drug, and Cosmetic Act.⁴¹⁰ Under FDA's statutory rules, citing an unrecognised third edition on a Declaration of Conformity without an exhaustive scientific justification is an administrative and regulatory non-conformity.¹⁰

What does a residual CoA that cites only the 2026 edition actually prove on a US-bound lot?

Consider the real-world operational scenario faced by an incoming quality engineer at a US medical device distributor: a shipment of sterile single-use circumcision devices arrives from an overseas contract manufacturer. The accompanying lot release certificate includes an EO residual Certificate of Analysis stating: 'Tested in accordance with ISO 10993-7:2026. Ethylene oxide: 2.1 mg/device; Ethylene chlorohydrin: 1.4 mg/device. Result: Pass.'¹⁴

Does this document satisfy the distributor's quality file and FDA premarket commitments? Without bridge documentation, the answer is no.⁴¹⁰ Under FDA guidance on the Appropriate Use of Voluntary Consensus Standards in Premarket Submissions for Medical Devices (issued September 2018), a Declaration of Conformity must attest to conformity with the specific standard listed in FDA's recognition database.¹⁰

When a lot is released against ISO 10993-7:2026 alone, several regulatory gaps immediately emerge:

• Absence of Consensus Recognition: FDA CDRH has not recognized ISO 10993-7:2026. A testing laboratory cannot grant regulatory recognition on FDA's behalf.⁴¹⁰
• Deviation from Cleared 510(k) Commitments: If the device's 510(k) summary committed to ISO 10993-7:2008/Amd 1:2019 under Rec 2-275, testing to a different standard represents an unassessed modification of the device's release specification.⁴¹¹
• Methodological Divergence: The 2026 edition introduces revised extraction procedures, alternative risk-assessment modeling for allowable limits, and modified duration categories.³ If the laboratory utilized extraction kinetics or allowable limits derived solely under 2026 Annexes without demonstrating equivalence to the extraction methods required under Rec 2-275, the data cannot be audited against FDA acceptance criteria.³⁴

To render an ISO 10993-7:2026 test report legally and technically valid for US commercial distribution, the quality file must contain an explicit bridge assessment.⁴¹⁰ This technical justification must demonstrate that: (1) the analytical extraction method (e.g., exhaustive solvent extraction or thermal desorption gas chromatography) meets or exceeds the analytical rigor of Rec 2-275; (2) the measured residue levels (mg/device) fall comfortably below the allowable numerical limits of Rec 2-275 for the specified contact duration; and (3) any subpopulation exposure factors comply with Amendment 1:2019.⁴ Merely waving a certificate with a '2026' banner is a failure of supplier quality assurance.

What does MDCG 2024-13 still cite, and why is EN ISO 11135:2014+A1:2019 not a residual-limit passport?

In the European Union, the regulatory status of ethylene oxide sterilization is governed by the General Safety and Performance Requirements (GSPR) set out in Annex I of Regulation (EU) 2017/745 (MDR). MDCG 2024-13 points specifically to MDR/IVDR Annex I sections 11.3–11.6 and 11.2–11.4 respectively.⁷ To clarify how notified bodies and manufacturers must document compliance, the Medical Device Coordination Group issued MDCG 2024-13 (Regulatory status of ethylene oxide (EtO) intended for the sterilisation of medical devices) in October 2024.⁷

Section 2.1 of MDCG 2024-13 identifies the European standards that further specify those MDR/IVDR Annex I sterilisation GSPR. The guidance writes “(harmonised) standards, such as” and then names:⁷

• EN ISO 11135:2014+A1:2019: Sterilization of health-care products — Ethylene oxide — Requirements for the development, validation and routine control of a sterilization process for medical devices.⁷⁸
• EN ISO 10993-7:2008+AC:2009+A1:2022: Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals.⁷
• EN 556-1:2024: Sterilisation of medical devices — Requirements for medical devices to be designated 'STERILE'.⁷

MDCG 2024-13 does not cite ISO 10993-7:2026.⁷ The parenthetical “(harmonised)” in that guidance is not a substitute for an Official Journal citation.⁹ Under Article 8(1) of the MDR, presumption of conformity is conferred exclusively by harmonised standards whose references have been published in the Official Journal of the European Union (OJEU).⁹ Commission Implementing Decision (EU) 2021/1182 publishes EN ISO 11135:2014 with EN ISO 11135:2014/A1:2019 in Recital 7 and annex item 2; it does not publish EN ISO 10993-7.⁸ Commission Implementing Decision (EU) 2026/1231 of 11 June 2026 later added EN ISO 10993-1:2025 (Part 1) to that annex and still did not cite EN ISO 10993-7:2026.¹⁵

A widespread error among procurement teams is conflating an ISO 11135 validation certificate with proof of residual conformity.⁸ As established in our EO sterilization validation acceptance guide, an ISO 11135 validation establishes that the physical sterilization cycle delivers a Sterility Assurance Level (SAL) of 10^-6 via biological indicator inactivation across half-cycle overkill testing.⁸ It qualifies the cycle parameters (preconditioning, gas concentration, dwell time, and heated aeration cell duration).⁸ However, ISO 11135 does not determine whether a finished production lot, after packaging and quarantine, contains less than the allowable milligrams of toxic EO or ECH residue.⁷⁸ Residual verification is exclusively the domain of ISO 10993-7.⁷

Nor should European buyers treat a national catalogue withdrawal as MDR harmonisation. ISO withdrew the 2008 second edition, Corrigendum 1:2009 and Amendment 1:2019 as ISO publications when it issued the 2026 third edition; that ISO-catalogue event does not alter the Official Journal list or the MDCG 2024-13 citation of EN ISO 10993-7:2008+AC:2009+A1:2022.¹⁷⁹ Table 2 summarizes how the three major global jurisdictions evaluate an incoming EO residual file in September 2026.

Are the 2008 4 mg EO / 9 mg ECH adult limited-contact figures still the FDA-recognised numbers, and are they a global regulator benchmark?

For almost two decades, the universal shorthand in medical device packaging and sterilization has been the '4 mg / 9 mg rule'.⁴ Under ISO 10993-7:2008 as recognised in Rec 2-275, devices with limited contact (≤ 24 hours cumulative exposure) are assessed against 4.0 mg of ethylene oxide (EO) and 9.0 mg of ethylene chlorohydrin (ECH) per device for an adult 70 kg default.⁴ The same 2008+Amd 1 text also sets prolonged- and permanent-contact constraints (including the 60 mg first-30-day and 2.5 g / 10.0 g lifetime figures used on this site's EO sterilization validation acceptance guide); this article does not rebuild that cycle-and-limit table.⁴

Are these 2008 figures still the FDA-recognized criteria? Yes, for adult limited-contact devices evaluated under Rec 2-275.⁴ Because FDA Rec 2-275 remains tied to the second edition, an adult single-use device submitted under a 510(k) or released for US distribution is assessed directly against the 4.0 mg EO and 9.0 mg ECH thresholds.⁴

However, calling 4 mg / 9 mg an unthinking 'global regulator benchmark for the 2026 edition'—the flattening already present in that EO-validation residual subsection—is the error this recognition file exists to correct.⁴ Public ISO catalogue and browsing-platform materials for ISO 10993-7:2026 describe a shift from tabulated adult limited-contact ceilings toward tolerable-intake values converted into subpopulation-specific milligram-per-device limits, with extraction conditions derived from patient population and duration of use.¹³ Those public notes are methodology, not FDA Rec 2-275, not an Official Journal citation, and not a licence to reprint paywalled 2026 milligram tables.³⁴

The public ISO Online Browsing Platform preview lists the main technical changes in the third edition, including population- and duration-derived limits, a permitted risk-assessment path for allowable limits, and additional product-release guidance.³ That preview is not Rec 2-275 and is not a licence to reprint 2026 milligram tables.³ Crucially, buyers must note another distinction already on the ISO catalogue abstract: ISO 10993-7:2026 explicitly does not specify device limits for ethylene glycol (EG).¹ The abstract states that the Annex F risk assessment indicates calculated allowable EG levels are higher than those likely to occur in a medical device.¹ Algorithmic search summaries that claim the 2026 edition imposes new, tighter numerical EG device limits contradict that public ISO note.¹

Does a pediatric or Children-type EO device wait for the 2026 edition, or is Amendment 1:2019 already inside Rec 2-275?

A dangerous myth circulating in supply chains is that pediatric, neonatal, and infant medical devices were completely unregulated with respect to special EO residual limits until the publication of ISO 10993-7:2026.¹⁴ Under this false narrative, suppliers tell distributors that a Children-type circumcision device or pediatric catheter can be released under the 4.0 mg adult ceiling until regulatory agencies formally mandate the 2026 edition.⁴

This assertion is false on the FDA recognition record.⁴ ISO 10993-7:2008 Amendment 1:2019, titled Applicability of allowable limits for neonates and infants, is already inside FDA Recognition 2-275.⁴ The official FDA title line includes that amendment.⁴ In Europe, the corresponding EN text is EN ISO 10993-7:2008+AC:2009+A1:2022, named in MDCG 2024-13 section 2.1.⁷

Amendment 1:2019 replaces the adult-only default in clauses 4.3.2–4.3.4: when the device is intended for special populations, the allowable limits shall be derived using the amendment’s specified tolerable-intake values and a justified body mass, not the unmodified adult 70 kg 4.0 mg / 9.0 mg ceilings.⁴ That is not a simple linear scale of 4.0 mg × (body mass / 70 kg). The amendment also requires the chosen default body mass for each special-population category to be justified and documented.⁴

Consequently, an OEM buyer or distributor qualifying a pediatric or Children-type SKU—such as the pediatric circumcision rings analyzed in our circumcision device sizing buyer guide—does not have to wait for the 2026 edition to reject a supplier's adult-rated CoA.⁴¹³ Releasing a Children-type lot against a generic adult 4.0 mg limit is a Rec 2-275 population-match failure under Amendment 1:2019, and it fails the MDCG 2024-13 EN citation that already includes A1:2022.⁴⁷ Table 3 contrasts the Rec 2-275 Amendment 1 test with the 2026 subpopulation methodology without printing paywalled milligram tables.

What should a China-bound file show under GB/T 16886.7, and why is that not ISO 10993-7:2026 by default?

For medical devices manufactured, registered, or distributed in the People's Republic of China, residual testing is governed by the national standards system and by the device's registered Product Technical Requirement (PTR / 产品技术要求).¹² The current Chinese national Part 7 method standard is GB/T 16886.7-2015 (Biological evaluation of medical devices — Part 7: Ethylene oxide sterilization residuals), a recommended (推荐性) national standard issued on 10 December 2015, effective 1 January 2017, and last reviewed on 28 December 2023 with the conclusion 继续有效.¹²

GB/T 16886.7-2015 is an identical adoption (IDT) of ISO 10993-7:2008.¹² A 2015 IDT is not proof that NMPA has rejected ISO 10993-7:2026; it is proof that the catalogue still lists the 2008 text as 现行.¹² When an NMPA registration certificate is issued, the PTR defines the binding product specification and release testing methods for that SKU. If the PTR cites GB/T 16886.7-2015, a 2026-only ISO header does not replace that citation.¹²

Do not paste a 4 mg / 9 mg slogan, a 10 μg/g factory slogan, or an ISO 10993-7:2026 header as if any of those were GB/T 16886.7-2015 itself.¹² The national Part 7 method standard is an IDT of the 2008 milligram-per-device contact-category text; a device-specific residual ceiling, if any, lives in the registered PTR and must be read there.¹² A China-bound residual report should name GB/T 16886.7-2015 and the PTR. A test report stating conformity only to ISO 10993-7:2026 does not close that file.¹²

Factory quality-system duties are a different file. As examined in the China NMPA GMP Announcement No. 107 factory qualification guide, Article 104's two-step production/listing release is about who signs the batch out of the plant, not a statutory milligram table for EO residuals. Residual limits belong in the registered process and in the records the release reviewer actually checks; they are not copied into Article 104 as a list. Mixing Announcement 107 personnel rules with Rec 2-275 or GB/T 16886.7 is the wrong test.

Worked examples: a CE-marked Adult circumcision ring versus a Children-type SKU versus an NMPA-only SKU with no EO claim, and why NOVACURE is out of scope

To ground these technical and regulatory distinctions in real-world commercial operations, consider five product configurations from the VEMERIX urological and minimally invasive portfolio.¹³¹⁴ As detailed in our registration landscape analysis in the circumcision device market entry evidence pack guide, different device configurations carry fundamentally different sterilisation release boundaries.¹³

• Worked Example 1: VEMERIX Circumcision Device (Adult Type): Registered under NMPA Lu Mech Reg. 20172020238, CE marked, and labelled for ethylene oxide sterilization.¹³ For European distribution, the release file must cite EN ISO 10993-7:2008+AC:2009+A1:2022 under MDCG 2024-13 and demonstrate EO < 4.0 mg / ECH < 9.0 mg.⁴⁷ For US entry, the file must align with FDA Rec 2-275.⁴ Citing only the 2026 ISO publication on the batch CoA leaves the European and US files open.¹⁴
• Worked Example 2: VEMERIX Circumcision Device (Children Type): Same NMPA registration and CE mark, offered as the Children-type SKU for pediatric urology.¹³ Presenting only an adult 4.0 mg CoA fails incoming inspection under Rec 2-275 Amendment 1:2019.⁴ The release file must show special-population derivation (justified body mass and Amd 1 TI path), not a promise that pediatric rules begin in April 2026.⁴⁷
• Worked Example 3: VEMERIX Disposable Circumcision Stapler: Registered under NMPA Lu Mech Reg. 20192020192, factory EO-sterilized, but without a European CE mark.¹⁴ Commercial release for domestic or non-EU markets is governed by GB/T 16886.7-2015 and target jurisdiction requirements.¹² Fabricating an EU MDR harmonisation claim or citing ISO 10993-7:2026 without national alignment is invalid.¹¹²
• Worked Example 4: Single-Use Endovenous Laser Fiber: Registered under NMPA Lu Mech Reg. 20192010517 and described as single-use and sterile.¹⁶ The public specification does not name ethylene oxide or any other sterilisation modality.¹⁶ Demanding an ISO 10993-7 EO residual dissipation curve for this SKU invents a process the product page does not record. If a later labelled process is radiation, the residual file is the radiation sterilization validation guide, not Part 7.
• Scope Boundary: NOVACURE Laser System: The NOVACURE diode laser system is a partner-supplied capital console used with Medison's registered single-use fiber.¹⁶ It is not manufactured by Medison as a sterile single-use consumable and is out of scope for ISO 10993-7 residual evaluation.

Distributor and OEM incoming checklist: edition on the CoA, contact category, population, method, dissipation curve, and the documents to request

To prevent regulatory delays, customs holds, and quality audit findings, international procurement teams and distributor quality managers should implement a rigorous 7-Gate Incoming EO Residual Acceptance Protocol.⁴⁷ When qualifying a sterile single-use device batch, audit the evidence pack against the gates detailed in Table 5.

Where VEMERIX fits—and where buyer due diligence still begins

VEMERIX is the international brand of Weihai Medison Medical Equipment Co., Ltd., positioned as a Minimally Invasive Surgery Total Solution Platform serving urology, vascular surgery and perioperative care.¹³ For EO-labelled urological consumables—the CE-marked Circumcision Device (Adult and Children types), the Circumcision Anastomat Kit, and the Disposable Circumcision Stapler—buyers can request the current sterilisation and residual pack rather than a claimed 2026-edition close-out.¹³¹⁴

That pack is the place to read the edition year, contact category, patient population and dissipation curve against Rec 2-275, MDCG 2024-13 and GB/T 16886.7-2015.⁴⁷¹² For Children-type circumcision rings, incoming inspection should require Amendment 1:2019 population matching; this article does not claim a published, SKU-level 2026-edition gap assessment or a public Amd 1 calculation sheet.⁴¹³

However, transparent commercial partnership demands absolute regulatory clarity: VEMERIX does not claim a premature or completed ISO 10993-7:2026 gap assessment.¹ Our technical dossiers and commercial batch releases are maintained strictly against the currently recognized and legally enforceable consensus standards: US FDA Recognition 2-275, European MDCG 2024-13 (EN ISO 10993-7:2008+AC:2009+A1:2022), and Chinese GB/T 16886.7-2015.⁴⁷¹²

Buyer due diligence begins by reviewing the device's technical file and target market clearances rather than accepting generic marketing claims.¹⁰ International distributors, private-label OEM partners, and clinical engineering teams can request technical dossiers, lot dissipation curves, and regulatory qualification files through our Quality Assurance Portal, inspect our urological and surgical consumables on the Products Portfolio, or schedule a technical audit via our Commercial Contact Gateway.

Frequently Asked Questions

Q1: Is ISO 10993-7:2026 the FDA-recognised residual standard in September 2026?
No. As of September 2026, FDA Recognition Number 2-275 remains the active consensus standard recognition. Rec 2-275 designates ISO 10993-7 Second edition 2008-10-15 [Including Technical Corrigendum 1 (2009) and Amendment 1 (2019)]. A live search of the FDA database for designation 10993-7 returns only one record, which was last updated on 25 May 2026 without adding the 2026 edition.⁴⁵

Q2: Did FDA's 25 May 2026 recognition of ISO 10993-1:2025 also recognise ISO 10993-7:2026?
No. On 25 May 2026, FDA published List 066 and added Rec 2-313, granting partial recognition to ISO 10993-1 Sixth edition 2025-11 (Part 1: Requirements and general principles for the evaluation of biological safety within a risk management process), with a transition window accepting Rec 2-258 until 1 July 2029. That update applied to Part 1. Part 7 was not given a new recognition number and has no published Part 7 transition window.⁴⁶

Q3: Does a residual CoA that cites ISO 10993-7 without an edition year close a US file?
No. Under FDA's voluntary consensus standards guidance, Declarations of Conformity must cite the exact recognized standard version. A CoA omitting the year or citing an unrecognised third edition leaves the submission open to deficiency letters or inspectional observations under 21 CFR 820 / QMSR.⁴¹⁰

Q4: Are 4 mg EO and 9 mg ECH still the FDA-recognised adult limited-contact limits?
Yes. Under FDA Rec 2-275 (ISO 10993-7:2008 including Amd 1:2019), 4.0 mg EO and 9.0 mg ECH remain the recognized allowable limits for adult limited-contact devices (≤ 24 hours). Public materials for ISO 10993-7:2026 describe a tolerable-intake derivation rather than a static table; that methodology is not, by itself, Rec 2-275.³⁴

Q5: Does a Children-type circumcision device need the 2026 edition before pediatric residual rules exist?
No. Amendment 1:2019 (Applicability of allowable limits for neonates and infants) is already an integral part of FDA Rec 2-275 and European standard EN ISO 10993-7:2008+A1:2022. Releasing a pediatric device under adult 70 kg limits is an immediate regulatory non-compliance today.⁴⁷

Q6: Does an ISO 11135 certificate prove residual limits?
No. ISO 11135:2014 governs the validation and control of the sterilization process to achieve a 10^-6 Sterility Assurance Level. It does not measure or certify that chemical residues on the finished device comply with ISO 10993-7 limits. A complete file requires both an ISO 11135 validation report and an ISO 10993-7 residual report.⁷⁸

Q7: Does GB/T 16886.7-2015 automatically follow ISO 10993-7:2026?
No. GB/T 16886.7-2015 remains the in-force recommended national Part 7 on the official catalogue (issued 2015-12-10, effective 2017-01-01, last reviewed 2023-12-28 as 继续有效) as an identical adoption of ISO 10993-7:2008. A China-bound file should name that GB/T and the registered PTR; it does not automatically become the 2026 ISO text.¹²

Q8: Does VEMERIX already hold a published 2026-edition residual gap assessment for these SKUs?
No. VEMERIX maintains its sterilization validation and residual release files against in-force recognized consensus standards (FDA Rec 2-275, MDCG 2024-13 EN 10993-7:2008+A1:2022, and GB/T 16886.7-2015). We do not claim a closed 2026-edition gap assessment, ensuring complete transparency with international buyers.⁴⁷¹³